Firstline pembrolizumab plus chemo improves NSCLC outcomes

Bookmark and Share
Published: 9 Oct 2016
Views: 1557
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Dr Corey Langer presents, at press conference at ESMO 2016, results from the KEYNOTE-021 trial.

The trial found that the addition of pembrolizumab, a PD-1 antibody, to standard first-line chemotherapy for treatment-naive advanced NSCLC achieved significantly longer progression free survival, a great objective response rate, and a well tolerated toxicity profile.

These results complement those presented by Dr Martin Reck, who presented results from KEYNOTE-024 which recommend pembrolizumab as a firstline therapy for NSCLC patients with high levels of PDL-1 expression.

More details are available in the trial data published in The Lancet.

Dr Langer spoke with ecancer about the findings here.